contact us Contact Us Or call +44 (0)118 979 1169
  • About
    • Who are GRA?
    • Meet the Founders
    • Associates
    • Testimonials
    • FAQs
  • Services
    • Biotech Consulting
    • Biotech Speaker
    • Training
  • Blog
  • Contact Us
  • Case Studies
  • Resources
    • Articles
    • Videos
    • Presentations
    • Free Templates
    • Newsletters
  • Search
  • Client Login
    • Trello
    • GoToMeeting
    • join me
  • Presentations
    • Balancing the statistical tightrope
    • The Analyst’s Perspective: Ensuring and Controlling Quality of Well-Characterized Biologics
    • Public-Private Coalition's: High-Profile Delinkage Policy For Emerging Vaccines
  • Newsletters
    • Balancing the statistical tightrope
    • The Analyst’s Perspective: Ensuring and Controlling Quality of Well-Characterized Biologics
    • Public-Private Coalition's: High-Profile Delinkage Policy For Emerging Vaccines
  • Free Templates
    • Balancing the statistical tightrope
    • The Analyst’s Perspective: Ensuring and Controlling Quality of Well-Characterized Biologics
    • Public-Private Coalition's: High-Profile Delinkage Policy For Emerging Vaccines
  • Videos
    • Balancing the statistical tightrope
    • The Analyst’s Perspective: Ensuring and Controlling Quality of Well-Characterized Biologics
    • Public-Private Coalition's: High-Profile Delinkage Policy For Emerging Vaccines
  • Articles
    • Balancing the statistical tightrope
    • The Analyst’s Perspective: Ensuring and Controlling Quality of Well-Characterized Biologics
    • Public-Private Coalition's: High-Profile Delinkage Policy For Emerging Vaccines

GRA Articles

Please feel free to read or download published articles written by or relating to GRA.  If you re-publish or use any excerpts from the articles, please remember to cite GRA or the author.

  • Public-Private Coalition's: High-Profile Delinkage Policy For Emerging Vaccines

    2017 article about CEPI's Public-Private Coalition's High-Profile Delinkage Policy For Emerging Vaccines.

    Read this article
  • The Analyst’s Perspective: Ensuring and Controlling Quality of Well-Characterized Biologics

    Read GRA's contribution to Bioprocess International's 'The State of the Industry' articles exploring use of statistics in the sector.

    Read this article
  • Balancing the statistical tightrope

    During one development meeting early in my industrial career, a process development group member asked me whether the value my group had reported in one result was okay to use. I con dently replied “Yes, it’s ne. It’s about 40, somewhere between 38 and 42. The other person raised his eyebrows. “About 40?” In response, I somewhat awkwardly mumbled “Yes, probably . . . about that” – an answer not met with full understanding, but rather concern.

    Read this article
  • Stay up
    to date

    Complete your details and we’ll send you regular updates via our newsletter.

  • Our newsletter



    • Resources

      Need to understand some element of the biopharma industry or looking for a particular template?

      Click here to see our free resources

    • About
      • Who are GRA?
      • Meet the Founders
      • Associates
      • Testimonials
      • FAQs
    • Services
      • Biotech Consulting
      • Biotech Speaker
      • Training
    • Blog
    • Contact Us
    • Case Studies
    • Resources
      • Articles
      • Videos
      • Presentations
      • Free Templates
      • Newsletters
    Terms & Conditions Privacy Policy Cookies FAQs

    © 2023 GreyRigge Associates Limited. All rights reserved.

    Site design & build by Hinge Ltd.